Johnson & Johnson (JNJ) Debt Ratio (2009 - 2026)

Johnson & Johnson (JNJ) posted Debt Ratio of 0.24 for Q2 2026, down 10.9% sequentially from 0.27 in Q1 2026, and down 7.08% YoY from 0.26 in Q2 2025.

Johnson & Johnson (JNJ) Debt Ratio (2009 - 2026) Analysis & Trends

Johnson & Johnson has reported Debt Ratio for 18 years, with the latest figure at 0.24 in Q2 2026.

Quarterly Debt Ratio fell 7.08% year-over-year to 0.24 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.24 (down 7.08% YoY) and the FY2025 annual result came in at 0.24, up 12.9% from the prior year.
Debt Ratio retreated to 0.24 in Q2 2026 per JNJ's latest filing, from 0.27 in the prior quarter.
Over five years, Debt Ratio peaked at 0.27 in Q1 2026 and troughed at 0.18 in Q4 2023.
A 5-year average of 0.22 and a median of 0.22 in 2023 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2023 and 2024: Debt Ratio surged 45.26% in 2023, then slipped 27.56% in 2024.
Over 5 years, Debt Ratio stood at 0.18 in 2022, then gained by 0.51% to 0.18 in 2023, then rose by 15.94% to 0.21 in 2024, then increased by 12.9% to 0.24 in 2025, then advanced by 1.36% to 0.24 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.24, 0.27, and 0.24 for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Johnson & Johnson	653.37 Bn	632.61 Bn	17.26 Bn	0.24
2	AbbVie	469.65 Bn	463.08 Bn	12.70 Bn	0.52
3	Merck	376.13 Bn	368.99 Bn	12.21 Bn	0.42
4	Novartis Ag	303.28 Bn	295.59 Bn	11.24 Bn	0.08
5	Astrazeneca	258.06 Bn	253.16 Bn	12.86 Bn	0.25
6	Amgen	236.35 Bn	222.36 Bn	7.24 Bn	0.66
7	Gilead Sciences	182.15 Bn	178.97 Bn	6.22 Bn	0.58
8	Pfizer	159.57 Bn	147.87 Bn	10.94 Bn	0.31
9	Gsk	106.24 Bn	102.07 Bn	8.24 Bn	-0.31
10	Sanofi	55.20 Bn	47.82 Bn	10.79 Bn	0.17

Download Data